AshHill is a private investment firm with a specialized focus on the biomedical sector and participating in its portfolio companies in active management roles, as well as scientific and support services. Its mission is to discover, analyze and invest in start-up, seed-stage and established companies that are working to develop medical innovations.

The firm’s leadership, including physicians, researchers, business professionals and entrepreneurs bring experience in the establishment, development, management and sale of pharmaceutical companies to optimize investments and help bring pharmaceuticals and medical devices through the regulatory process and into the marketplace.

Combination of experience

AshHill ShortLine
Ash Hill’s leadership team offers expertise in the biomedical industry as well as extensive experience growing biomedical companies from start-up and seed-stage to mature companies. We combine that with business and investing experience to offer our investors and our invested companies a proven track record.

Active management role

AshHill ShortLine
AshHill takes active management roles in its portfolio companies. The firm’s leadership team members take board seats and key leadership positions to offer their business experience and industry knowledge to the companies they are working alongside. For example, Dr. Peter Milner is currently serving as CEO of Heart Metabolics, Dave Buffenbarger is serving as CFO and VP of Finance for Armetheon, Inc., and Steven R. Smith is on the board of directors at Heart Metabolics.

Focus on medical need

AshHill ShortLine
The AshHill team evaluates each investment opportunity on specific criteria that includes the financial potential of the company. But the approach goes beyond the numbers; AshHill Biomedical Investments is also focused on areas of unmet medical need. With clinical expertise, the team is able to compare a potential investment company’s methodology to existing treatments, diagnostic tools or prevention methods.

AshHill Line

By recognizing truly breakthrough technologies, we identify companies that have the potential to improve the health and wellness of under-served populations or address issues that are being ignored by larger companies. The regulatory track success of our portfolio companies demonstrates our ability to identify companies that have a strong likelihood of success in their endeavors.

AshHill Line

Armetheon closes $24 million Series B financing

Menlo Park, CA – February 5, 2015 – Armetheon, Inc., a cardiovascular disease-focused, clinical stage, specialty biopharmaceutical company, today announced the successful closing of $24.3 million in Series B financing. The financing was co-led by Hercules Bioventure Partners and Capital TEN II, with participation from new and existing investors. The funds will mainly be used to advance Armetheon’s lead clinical candidate, tecarfarin, which is being investigated as a novel vitamin-K-antagonist (VKA) oral anticoagulant that avoids adverse drug reactions associated with the current standard-of-care, warfarin. Tecarfarin’s final pivotal clinical study (Tecarfarin for AntiCoagulation Trial or “TACT”) will compare tecarfarin with warfarin in patients with any indication that requires oral anticoagulation, including underserved populations such as patients who respond poorly to warfarin, and patients with prosthetic heart valves for whom novel oral anticoagulants such as the anti-thrombin or Factor Xa inhibitors are either contraindicated or not recommended by professional society guidelines. Armetheon’s 3,000-patient, open-label, real world pivotal trial of tecarfarin will be conducted under a Special Protocol Assessment agreed upon with the FDA in April 2014. “We are very pleased by the high degree of commitment from both institutional and angel investors in our Series B financing round. The funds will primarily be used to advance tecarfarin’s new drug application filing timeline and to build an expanded organization to support Armetheon’s core mission of obtaining regulatory approval for tecarfarin in the US,” said M. (Ken) Kengatharan, Ph.D., President and Interim CEO of Armetheon. In addition to co-leads Hercules Bioventure Partners and Capital TEN II, firms with significant participation in the financing included China Development Industrial Bank (CDIB) Healthcare, CDIB & Partners, iD SoftCapital Group and... read more

Armetheon Completes $7.0 Million Series A Financing

Menlo Park, CA – August 28, 2014 — Armetheon, Inc. (, a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The Series A round was co-led by AshHill Biomedical Investments and Hercules Bioventures with participation from investors that included Atheneos Capital and eminent biotech entrepreneur and pharmaceutical executive, Dr. Larry Hsu, the founder of Impax Laboratories (NASDAQ: IPXL). Earlier this year the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial, TACT (Tecarfarin for AntiCoagulation Trial), for Tecarfarin, which is being investigated for all patients who require an oral anticoagulant (OAC), including patients with mechanical heart valves  (MHV). Recent clinical guidelines from AHA/ACC recommend the use of a vitamin-K antagonist (VKA) for anticoagulation in patients with a MHV.  The guidelines also recommend MHV over bioprosthetic heart valves for patients who are less than 60 years of age. The results from already completed clinical trials and TACT will form the basis of regulatory submission for Tecarfarin. “The quality of our science and the team is reflected by the stellar syndicate of both institutional and angel investors in this over-subscribed Series A round,” said M. (Ken) Kengatharan, PhD, Co-Founder, President & COO. “The funds will be used to keep to our NDA filing timeline in 2017 for Tecarfarin,”said Peter Milner MD, FACC Co-Founder and Chairman of Armetheon. “Tecarfarin, if approved, could become an important alternative VKA that is not metabolized via CYP enzymes or handled by P-glycoprotein (P-gp).Studies have shown... read more

AshHill Biomedical Investments announces recent regulatory approvals for several ventures

Cincinnati, Ohio – AshHill Biomedical Investments, a U.S.-based private investment firm specializing in biomedical opportunities, announced several of its ventures recently passed significant FDA approval hurdles – including Orphan Drug Designation for a medication developed by one company and a Special Protocol Assessment (SPA) agreement for another company’s pharmaceutical. Among the companies AshHill has invested in: Armetheon, a pharmaceutical company offering an anticoagulant medication for patients with heart disease Heart Metabolics, a pharmaceutical company offering a drug for a hereditary heart disease Sinusys, a medical device company developing a minimally invasive treatment for sinusitis Recently, each of the companies made significant regulatory announcements. In April, Armetheon announced that it had reached a SPA agreement with the U.S. FDA for a Phase 3 trial of tecarfarin. At the same time, perhexiline, a medication from Heart Metabolics, received an Orphan Drug Designation from the FDA for treating hypertrophic cardiomyopathy, a hereditary heart disease. At Sinusys, the FDA cleared its Vent-Os sinus dilation system for use in January of this year. “We’re so proud to be a part of bringing these medical innovations to the patients who need them,” said Dr. Peter Milner, Managing Director of AshHill Biomedical Investments. “We have a vision to use our investments and our expertise to meet unmet medical needs. Each of these great companies is doing that, and they’ve been successfully clearing the regulatory hurdles to bring these treatment options to doctors and their patients.” As part of its investment strategy, AshHill takes active management roles, as well as scientific and support services, in the companies it invests in. Milner, who co-founded Optiva Biotechnology, CV Therapeutics... read more